Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 3/20 | 0.51 |
| ▸ | CA6 | P23280 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 5/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | CDK9 | P50750 | 2/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CCNH | P51946 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31444232 | 0.90 | CA1 (0.52) | CDK1CA1CA2CA9CA12 | |
| SCHEMBL5561870 | 0.87 | CDK2 (0.64) | CDK1PTK2AURKAAURKBCDK2 | |
| SCHEMBL31180415 | 0.85 | PTK2 (0.56) | CDK1PTK2AURKACDK2CCNT1 | |
| SCHEMBL31180414 | 0.85 | PTK2 (0.56) | CDK1PTK2AURKACDK2CCNT1 | |
| SCHEMBL1917337 | 0.82 | STK17A (0.60) | CDK1PTK2AURKAKDR | |
| SCHEMBL31444285 | 0.82 | LRRK2 (0.50) | CDK1CA1CA2CA9PTK2 | |
| SCHEMBL29631616 | 0.82 | PTK2 (0.49) | CDK1PTK2AURKACDK2CCNT1 | |
| SCHEMBL24477765 | 0.81 | CDK2 (0.60) | CDK1CA1CA2CA9PTK2 | |
| SCHEMBL15506892 | 0.81 | AURKA (0.48) | CDK1PTK2AURKACDK2KDR | |
| SCHEMBL3284454 | 0.80 | CDK1 (0.53) | CDK1PTK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4532473-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119343333-A | Amino heteroaryl kinase inhibitors | 安锐生物医药公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240166635-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc | 2024-05-23 | — | — | US | disclosed |
| EP-4251613-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116528869-A | Amino heteroaryl kinase inhibitors | 安锐生物医药科技(广州)有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
| CN-100465164-C | CF3Selective synthesis of-substituted pyrimidines | PFIZER (US) | 2009-03-04 | — | — | CN | disclosed |
| EP-1663991-B1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PROD INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7122670-B2 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| CN-1845906-A | Selective synthesis of CF 3-substituted pyrimidines | PFIZER (US) | 2006-10-11 | — | — | CN | disclosed |
| EP-1663991-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | Pfizer Products Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005023780-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PRODUCTS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | HNRNPH3, HNRNPA3, NUDT1 | CDK1 541/4885CA1 2896/4885CA2 3640/4885 |
| US-20240166635-A1 | AMINOHETEROARYL KINASE INHIBITORS | CDK2, CDK3, CDKL1 | CDK1 6/4885CA1 4314/4885CA2 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.